Log in
NASDAQ:STIM

Neuronetics Stock Forecast, Price & News

$4.34
-0.02 (-0.46 %)
(As of 09/25/2020 08:00 PM ET)
Add
Compare
Today's Range
$4.19
Now: $4.34
$4.40
50-Day Range
$3.52
MA: $4.54
$5.87
52-Week Range
$1.25
Now: $4.34
$9.47
Volume6,046 shs
Average Volume553,853 shs
Market Capitalization$81.86 million
P/E RatioN/A
Dividend YieldN/A
Beta2.53
Neuronetics, Inc., a commercial stage medical technology company, designs, develops, and markets products for patients with psychiatric disorders in the United States, Japan, and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder. Its NeuroStar Advanced Therapy System uses transcranial magnetic stimulation to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company sells its products through its sales and customer support team to psychiatrist customers. Neuronetics, Inc. was founded in 2003 and is headquartered in Malvern, Pennsylvania.
Read More
Neuronetics logo

Beat the Market (BTM) Rank

Analyst Opinion: 2.4Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.32 out of 5 stars


Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:STIM
CUSIPN/A
CIKN/A
Phone610-640-4202

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$62.66 million
Book Value$2.57 per share

Profitability

Net Income$-29,040,000.00

Miscellaneous

Employees191
Market Cap$81.86 million
Next Earnings Date11/3/2020 (Estimated)
OptionableNot Optionable
$4.34
-0.02 (-0.46 %)
(As of 09/25/2020 08:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive STIM News and Ratings via Email

Sign-up to receive the latest news and ratings for STIM and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Neuronetics (NASDAQ:STIM) Frequently Asked Questions

How has Neuronetics' stock price been impacted by COVID-19 (Coronavirus)?

Neuronetics' stock was trading at $2.07 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, STIM stock has increased by 109.7% and is now trading at $4.34.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Neuronetics?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Neuronetics in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Neuronetics
.

When is Neuronetics' next earnings date?

Neuronetics is scheduled to release its next quarterly earnings announcement on Tuesday, November 3rd 2020.
View our earnings forecast for Neuronetics
.

How were Neuronetics' earnings last quarter?

Neuronetics Inc (NASDAQ:STIM) posted its quarterly earnings results on Tuesday, August, 4th. The company reported ($0.41) earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($0.51) by $0.10. The firm earned $9.74 million during the quarter, compared to analyst estimates of $8.38 million. Neuronetics had a negative net margin of 63.77% and a negative return on equity of 82.79%.
View Neuronetics' earnings history
.

What price target have analysts set for STIM?

4 analysts have issued 12 month target prices for Neuronetics' shares. Their forecasts range from $4.00 to $6.00. On average, they expect Neuronetics' share price to reach $5.33 in the next year. This suggests a possible upside of 22.9% from the stock's current price.
View analysts' price targets for Neuronetics
.

Are investors shorting Neuronetics?

Neuronetics saw a increase in short interest during the month of September. As of September 15th, there was short interest totaling 834,700 shares, an increase of 34.9% from the August 31st total of 618,800 shares. Based on an average daily trading volume, of 849,800 shares, the short-interest ratio is presently 1.0 days. Currently, 7.2% of the company's stock are short sold.
View Neuronetics' Short Interest
.

Who are some of Neuronetics' key competitors?

What other stocks do shareholders of Neuronetics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Neuronetics investors own include SCYNEXIS (SCYX), Inovio Pharmaceuticals (INO), Novavax (NVAX), Onconova Therapeutics (ONTX), Ibio (IBIO), Pfizer (PFE), Tonix Pharmaceuticals (TNXP), Vaxart (VXRT), Acasti Pharma (ACST) and Biocept (BIOC).

Who are Neuronetics' key executives?

Neuronetics' management team includes the following people:
  • Mr. Christopher A. Thatcher, CEO, Pres & Director (Age 54)
  • Mr. Peter L. Donato, CFO, VP & Corp. Sec. (Age 49)
  • Mr. Gregory Harper, VP of R&D, Operations and Product Devel. (Age 58)
  • Ms. Cassie Hallberg, VP of Marketing
  • Mr. Daniel Guthrie, Chief Commercial Officer & VP (Age 42)

When did Neuronetics IPO?

(STIM) raised $75 million in an IPO on Thursday, June 28th 2018. The company issued 5,000,000 shares at $14.00-$16.00 per share. Piper Jaffray and William Blair served as the underwriters for the IPO and Canaccord Genuity, BTIG and JMP Securities were co-managers.

What is Neuronetics' stock symbol?

Neuronetics trades on the NASDAQ under the ticker symbol "STIM."

Who are Neuronetics' major shareholders?

Neuronetics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Deerfield Management Company L.P. Series C (8.98%), Bridgeway Capital Management Inc. (1.36%), Bellevue Group AG (1.33%), Two Sigma Advisers LP (0.76%), Blair William & Co. IL (0.72%) and Bank of New York Mellon Corp (0.35%). Company insiders that own Neuronetics stock include Brian E Farley, Christopher Thatcher, Daniel Guthrie, Gregory Harper, Peter Donato, Stephen Furlong, Stephen M Campe and William Andrew Macan.
View institutional ownership trends for Neuronetics
.

Which institutional investors are selling Neuronetics stock?

STIM stock was sold by a variety of institutional investors in the last quarter, including Bellevue Group AG, Blair William & Co. IL, Goldman Sachs Group Inc., and Algert Global LLC.
View insider buying and selling activity for Neuronetics
.

Which institutional investors are buying Neuronetics stock?

STIM stock was bought by a variety of institutional investors in the last quarter, including Bridgeway Capital Management Inc., Deerfield Management Company L.P. Series C, Jane Street Group LLC, Verition Fund Management LLC, Bank of New York Mellon Corp, Engineers Gate Manager LP, Two Sigma Advisers LP, and Bank of America Corp DE. Company insiders that have bought Neuronetics stock in the last two years include Brian E Farley, Daniel Guthrie, Gregory Harper, Stephen Furlong, Stephen M Campe, and William Andrew Macan.
View insider buying and selling activity for Neuronetics
.

How do I buy shares of Neuronetics?

Shares of STIM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Neuronetics' stock price today?

One share of STIM stock can currently be purchased for approximately $4.34.

How big of a company is Neuronetics?

Neuronetics has a market capitalization of $81.86 million and generates $62.66 million in revenue each year. The company earns $-29,040,000.00 in net income (profit) each year or ($1.58) on an earnings per share basis. Neuronetics employs 191 workers across the globe.

What is Neuronetics' official website?

The official website for Neuronetics is www.neurostar.com.

How can I contact Neuronetics?

Neuronetics' mailing address is 3222 PHOENIXVILLE PIKE, MALVERN PA, 19355. The company can be reached via phone at 610-640-4202 or via email at [email protected]

This page was last updated on 9/28/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.